BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Kim SE, Park MI, Park SJ, Moon W, Kim JH, Jung K, Kim HK, Lee YD. Second-line bismuth-containing quadruple therapy for Helicobacter pylori eradication and impact of diabetes. World J Gastroenterol 2017; 23(6): 1059-1066 [PMID: 28246480 DOI: 10.3748/wjg.v23.i6.1059]
URL: https://www.wjgnet.com/1007-9327/full/v23/i6/1059.htm
Number Citing Articles
1
Marina Valenzano, Alessandro Bisio, Giorgio Grassi. Helicobacter pylori and diabetes mellitus: a controversial relationshipMinerva Endocrinologica 2019; 44(3) doi: 10.23736/S0391-1977.19.03021-9
2
Natsuda Aumpan, Varocha Mahachai, Ratha‐korn Vilaichone. Management of Helicobacter pylori infectionJGH Open 2023; 7(1): 3 doi: 10.1002/jgh3.12843
3
Sung Eun Kim. Effect of Diabetes Mellitus on Helicobacter pylori Eradication TherapyThe Korean Journal of Helicobacter and Upper Gastrointestinal Research 2017; 17(2): 59 doi: 10.7704/kjhugr.2017.17.2.59
4
Anthony O'Connor, Dominique Lamarque, Javier P. Gisbert, Colm O'Morain. Treatment of Helicobacter pylori infection 2017Helicobacter 2017; 22(S1) doi: 10.1111/hel.12410
5
Sung Eun Kim. Approach to Patients with Consecutive Helicobacter pylori Eradication FailureThe Korean Journal of Helicobacter and Upper Gastrointestinal Research 2023; 23(1): 15 doi: 10.7704/kjhugr.2023.0017
6
Hyun Lim, Chang Seok Bang, Woon Geon Shin, Jae Ho Choi, Jae Seung Soh, Ho Suk Kang, Young Joo Yang, Ji Taek Hong, Suk Pyo Shin, Ki Tae Suk, Jae Jun Lee, Gwang Ho Baik, Dong Joon Kim. Modified quadruple therapy versus bismuth-containing quadruple therapy in first-line treatment of Helicobacter pylori infection in Korea; rationale and design of an open-label, multicenter, randomized controlled trialMedicine 2018; 97(46): e13245 doi: 10.1097/MD.0000000000013245
7
Sung Eun Kim, Ji Hun Roh, Moo In Park, Seun Ja Park, Won Moon, Jae Hyun Kim, Kyoungwon Jung, Jae Joon Heo. Effect of 7-day Bismuth Quadruple Therapy versus 14-day Moxifloxacin Triple Therapy for Second-line Helicobacter pylori Eradication TherapyThe Korean Journal of Gastroenterology 2019; 73(1): 26 doi: 10.4166/kjg.2019.73.1.26
8
Kiwon Shin, Min-Jae Cho, Jung-Hwan Oh, Chul-Hyun Lim. Second-Line Bismuth-Containing Quadruple Therapy for Helicobacterpylori Infection: A 12-Year Study of Annual Eradication RatesJournal of Clinical Medicine 2021; 10(15): 3273 doi: 10.3390/jcm10153273
9
Multiple drugsReactions Weekly 2017; 1653(1): 224 doi: 10.1007/s40278-017-30652-8
10
Sung Eun Kim. Can Proton Pump Inhibitors Affect Helicobacter pylori Eradication Therapy?The Korean Journal of Helicobacter and Upper Gastrointestinal Research 2020; 20(3): 173 doi: 10.7704/kjhugr.2019.0050
11
Mohammed Mohammed, Dunya Arif, Mohsin Mohammed. THE EVALUATION OF TRIPLE, QUADRUPLE, AND LEVOFLOXACIN-BASED THERAPY IN THE MANAGEMENT OF HELICOBACTER PYLORI INFECTION AMONG DYSPEPTIC PATIENTSJOURNAL OF SULAIMANI MEDICAL COLLEGE 2019; 9(1): 45 doi: 10.17656/jsmc.10189
12
Gil Ho Lee, Kee Myung Lee, Sung Jae Shin, Joon Koo Kang, Choong-Kyun Noh, Jin Hong Kim, Sun Gyo Lim. Impact of previous metronidazole exposure on metronidazole-based second-line quadruple therapy for Helicobacter pylori infection The Korean Journal of Internal Medicine 2020; 35(5): 1094 doi: 10.3904/kjim.2020.174
13
Jung Won Lee, Nayoung Kim, Ryoung Hee Nam, Sun Min Lee, Choi Soo In, Jung Mogg Kim, Dong Ho Lee. Risk factors of rescue bismuth quadruple therapy failure for Helicobacter pylori eradicationJournal of Gastroenterology and Hepatology 2019; 34(4): 666 doi: 10.1111/jgh.14625
14
Xin Song, Changzhou Cai, Qi Jin, Xueyang Chen, Chaohui Yu. The efficacy of Helicobacter pylori eradication in diabetics and its effect on glycemic control: A systematic review and meta‐analysisHelicobacter 2021; 26(2) doi: 10.1111/hel.12781